Anemia, Sickle Cell Clinical Trial
Official title:
Protocol for the Administration of Hydroxyurea During Painful Vaso-occlusive Crisis in Sickle Cell Anemia
This study will investigate the safety, tolerability and potential for the use of up to three daily doses of 30-40 mg/kg HU (daily) upon hospitalization for painful vaso-occlusive crises .
Sickle cell anemia (SCA) is a hereditary hemoglobinopathy; complications of the disease
include, spleen enlargement, acute chest syndrome, pulmonary hypertension, stroke and
cumulative damage to multiple organs, and painful vaso-occlusive crises (VOC). In Brazil,
about 3,500 children are born each year with DF, and the number of individuals with sickle
cell disease (DF) in the country is estimated between 25,000 and 30,000 (ANVISA 2012;
BRAZIL, 2012).
Hydroxyurea (HU, or hydroxycarbamide) is the only drug approved to date by the American FDA
for use in adults with sickle cell disease. The drug modifies the disease process, improving
hematological parameters and the hospitalization time of patients, as well as the frequency
of vaso-occlusive crises.In addition to its proven effects during chronic use, experimental
data indicate that HU has immediate anti-inflammatory effects.
In addition to its proven effects during chronic use, experimental data indicate that HU has
immediate anti-inflammatory effects. This study will investigate the safety, tolerability
and potential for the use of up to three daily doses of 30-40 mg/kg HU (daily) upon
hospitalization for VOC.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06078696 -
Siplizumab for Sickle Cell Disease Transplant
|
Phase 1/Phase 2 | |
| Completed |
NCT04134299 -
To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease
|
N/A | |
| Completed |
NCT02561312 -
Comparison of Two Methods of Transfusion for Stroke Prevention in Sickle Cell
|
||
| Completed |
NCT00890396 -
Long-Term Effects of Hydroxyurea in Children With Sickle Cell Anemia (The BABY HUG Follow-up Study)
|
||
| Completed |
NCT00059293 -
Transcranial Doppler (TCD) Ultrasound of Subjects Enrolled in BABY HUG - Ancillary to BABY HUG
|
||
| Terminated |
NCT00034528 -
Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia
|
Phase 2 | |
| Completed |
NCT00005277 -
Cooperative Study of The Clinical Course of Sickle Cell Disease
|
N/A | |
| Active, not recruiting |
NCT04170348 -
Daily Vitamin D for Sickle-cell Respiratory Complications
|
Phase 2 | |
| Completed |
NCT04584528 -
Implementing an Individualized Pain Plan (IPP) for ED Treatment of VOE's in Sickle Cell Disease
|
N/A | |
| Recruiting |
NCT02286154 -
Therapeutic Response Evaluation and Adherence Trial (TREAT)
|
N/A | |
| Completed |
NCT02857023 -
Feasibility and Efficacy of a Home-based, Computerized Cognitive Training Program in Pediatric Sickle Cell Disease
|
N/A | |
| Withdrawn |
NCT01925001 -
Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis
|
Phase 2 | |
| Terminated |
NCT00122980 -
Stroke With Transfusions Changing to Hydroxyurea
|
Phase 3 | |
| Completed |
NCT00246077 -
Quality of Life of Children With Sickle Cell Disease Who Are Getting Chronic Transfusions With a Lifeport
|
N/A | |
| Completed |
NCT00094887 -
Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises
|
Phase 2 | |
| Completed |
NCT00035763 -
Pain in Sickle Cell Epidemiologic Study
|
N/A | |
| Terminated |
NCT04091737 -
CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease
|
Phase 1 | |
| Completed |
NCT00005300 -
Investigation of Selected Patient Groups From The Cooperative Study of Sickle Cell Disease
|
N/A | |
| Recruiting |
NCT04351698 -
SMILES: Study of Montelukast in Sickle Cell Disease
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05087303 -
Telemedicine for Children With Sickle Cell Disease
|
N/A |